• 1. Henson JB, Grumbles LC. Infectious bovine keratoconjunctivitis. I. Etiology. Am J Vet Res 1960; 21: 761766.

  • 2. Iwasa M, Kawada A, Yorita M, et al. Prolonged occurrence of Moraxella bovis infection on a restricted heifer farm. J Vet Med Sci 1994; 56: 429432.

    • Search Google Scholar
    • Export Citation
  • 3. Conceição FR, Paolicchi F, Cobo AL, et al. Antigenic relationships of Moraxella bovis isolates recovered from outbreaks of infectious bovine keratoconjunctivitis in Argentina, Brazil, and Uruguay between 1983 and 2000. Can J Vet Res 2003; 67: 315318.

    • Search Google Scholar
    • Export Citation
  • 4. Alexander D. Infectious bovine keratoconjunctivitis: a review of cases in clinical practice. Vet Clin North Am Food Anim Pract 2010; 26: 487503.

    • Search Google Scholar
    • Export Citation
  • 5. Schnee C, Heller M, Schubert E, et al. Point prevalence of infection with Mycoplasma bovoculi and Moraxella spp. in cattle at different stages of infectious bovine keratoconjunctivitis. Vet J 2015; 203: 9296.

    • Search Google Scholar
    • Export Citation
  • 6. Nayar PS, Saunders JR. Infectious bovine keratoconjunctivitis I. Experimental production. Can J Comp Med 1975; 39: 2231.

  • 7. Yeruham I, Perl S, Elad D. Infectious bovine keratoconjunctivitis and lymphofollicular hyperplasia of the third eyelid in heifers. J Vet Med B Infect Dis Vet Public Health 2001; 48: 137141.

    • Search Google Scholar
    • Export Citation
  • 8. Barner RD. A study of Moraxella bovis and its relation to bovine keratitis. Am J Vet Res 1952; 13: 132144.

  • 9. Misiura M. Keratoconjunctivitis infectiosa in calves—attempt at elimination by active immunization. Arch Vet Pol 1994; 34: 187194.

    • Search Google Scholar
    • Export Citation
  • 10. Angelos JA, Dueger EL, George LW, et al. Efficacy of florfenicol for treatment of naturally occurring infectious bovine keratoconjunctivitis. J Am Vet Med Assoc 2000; 216: 6264.

    • Search Google Scholar
    • Export Citation
  • 11. Dueger EL, Angelos JA, Cosgrove S, et al. Efficacy of florfenicol in the treatment of experimentally induced infectious bovine keratoconjunctivitis. Am J Vet Res 1999; 60: 960964.

    • Search Google Scholar
    • Export Citation
  • 12. Dueger EL, George LW, Angelos JA, et al. Efficacy of a long-acting formulation of ceftiofur crystalline-free acid for the treatment of naturally occurring infectious bovine keratoconjunctivitis. Am J Vet Res 2004; 65: 11851188.

    • Search Google Scholar
    • Export Citation
  • 13. Moore LJ, Rutter JM. Attachment of Moraxella bovis to calf corneal cells and inhibition by antiserum. Aust Vet J 1989; 66: 3942.

  • 14. Ruehl WW, Marrs C, Beard MK, et al. Q pili enhance the attachment of Moraxella bovis to bovine corneas in vitro. Mol Microbiol 1993; 7: 285288.

    • Search Google Scholar
    • Export Citation
  • 15. Annuar BO, Wilcox GE. Adherence of Moraxella bovis to cell cultures of bovine origin. Res Vet Sci 1985; 39: 241246.

  • 16. Beard MK, Moore LJ. Reproduction of bovine keratoconjunctivitis with a purified haemolytic and cytotoxic fraction of Moraxella bovis. Vet Microbiol 1994; 42: 1533.

    • Search Google Scholar
    • Export Citation
  • 17. Gray JT, Fedorka-Cray PJ, Rogers DG. Partial characterization of a Moraxella bovis cytolysin. Vet Microbiol 1995; 43: 183196.

  • 18. Kagonyera GM, George LW, Munn R. Cytopathic effects of Moraxella bovis on cultured bovine neutrophils and corneal epithelial cells. Am J Vet Res 1989; 50: 1017.

    • Search Google Scholar
    • Export Citation
  • 19. Lehr C, Jayappa HG, Goodnow RA. Serologic and protective characterization of Moraxella bovis pili. Cornell Vet 1985; 75: 484492.

  • 20. Jayappa HG, Lehr C. Pathogenicity and immunogenicity of piliated and nonpiliated phases of Moraxella bovis in calves. Am J Vet Res 1986; 47: 22172221.

    • Search Google Scholar
    • Export Citation
  • 21. Lepper AW, Atwell JL, Lehrbach PR, et al. The protective efficacy of cloned Moraxella bovis pili in monovalent and multivalent vaccine formulations against experimentally induced infectious bovine keratoconjunctivitis (IBK). Vet Microbiol 1995; 45: 129138.

    • Search Google Scholar
    • Export Citation
  • 22. Lepper AW, Elleman TC, Hoyne PA, et al. A Moraxella bovis pili vaccine produced by recombinant DNA technology for the prevention of infectious bovine keratoconjunctivitis. Vet Microbiol 1993; 36: 175183.

    • Search Google Scholar
    • Export Citation
  • 23. Lepper AW. Vaccination against infectious bovine keratoconjunctivitis: protective efficacy and antibody response induced by pili of homologous and heterologous strains of Moraxella bovis. Aust Vet J 1988; 65: 310316.

    • Search Google Scholar
    • Export Citation
  • 24. Moore LJ, Lepper AW. A unified serotyping scheme for Moraxella bovis. Vet Microbiol 1991; 29: 7583.

  • 25. Marrs CF, Ruehl WW, Schoolnik GK, et al. Pilin-gene phase variation of Moraxella bovis is caused by an inversion of the pilin genes. J Bacteriol 1988; 170: 30323039.

    • Search Google Scholar
    • Export Citation
  • 26. Angelos JA, Ball LM. Relatedness of cytotoxins from geographically diverse isolates of Moraxella bovis. Vet Microbiol 2007; 124: 382386.

    • Search Google Scholar
    • Export Citation
  • 27. Ostle AG, Rosenbusch RF. Immunogenicity of Moraxella bovis hemolysin. Am J Vet Res 1985; 46: 10111014.

  • 28. Billson FM, Hodgson JL, Egerton JR, et al. A haemolytic cell-free preparation of Moraxella bovis confers protection against infectious bovine keratoconjunctivitis. FEMS Microbiol Lett 1994; 124: 6973.

    • Search Google Scholar
    • Export Citation
  • 29. George LW, Borrowman AJ, Angelos JA. Effectiveness of a cytolysin-enriched vaccine for protection of cattle against infectious bovine keratoconjunctivitis. Am J Vet Res 2005; 66: 136142.

    • Search Google Scholar
    • Export Citation
  • 30. Angelos JA, Hess JF, George LW. Prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant Moraxella bovis cytotoxin-ISCOM matrix adjuvanted vaccine. Vaccine 2004; 23: 537545.

    • Search Google Scholar
    • Export Citation
  • 31. Kagonyera GM, George LW, Munn R. Light and electron microscopic changes in corneas of healthy and immunomodulated calves infected with Moraxella bovis. Am J Vet Res 1988; 49: 386395.

    • Search Google Scholar
    • Export Citation
  • 32. Pedersen KB. The origin of immunoglobulin-G in bovine tears. Acta Pathol Microbiol Scand B Microbiol Immunol 1973; 81: 245252.

  • 33. Nielsen K, Duncan JR. Bovine IgM: does it fix guinea pig complement in the absence of bovine complement components? Vet Immunol Immunopathol 1987; 14: 335343.

    • Search Google Scholar
    • Export Citation
  • 34. Vaerman JP, Heremans JF. Effect of neuraminidase and acidification on complement-fixing properties of human IgA and IgG. Int Arch Allergy Appl Immunol 1968; 34: 4952.

    • Search Google Scholar
    • Export Citation
  • 35. Marnila P, Korhonen H. Milk proteins: immunoglobulins. In: Fuquay JW, Fox PF, McSweeney PLH, eds. Encyclopedia of dairy sciences. 2nd ed. Cambridge, Mass: Academic Press, 2011; 807815.

    • Search Google Scholar
    • Export Citation
  • 36. Angelos JA, Edman JM, Chigerwe M. Ocular immune responses in steers following intranasal vaccination with recombinant Moraxella bovis cytotoxin adjuvanted with polyacrylic acid. Clin Vaccine Immunol 2014; 21: 181187.

    • Search Google Scholar
    • Export Citation
  • 37. Horwitz J. Alpha-crystallin can function as a molecular chaperone. Proc Natl Acad Sci U S A 1992; 89: 1044910453.

  • 38. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156159.

    • Search Google Scholar
    • Export Citation
  • 39. Studier FW, Rosenberg AH, Dunn JJ, et al. Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol 1990; 185: 6089.

    • Search Google Scholar
    • Export Citation
  • 40. Nagai K, Thøgersen HC. Synthesis and sequence-specific proteolysis of hybrid proteins produced in Escherichia coli. Methods Enzymol 1987; 153: 461481.

    • Search Google Scholar
    • Export Citation
  • 41. Wang G, Pan L, Zhang Y, et al. Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge. PLoS ONE 2011; 6: e27605.

    • Search Google Scholar
    • Export Citation
  • 42. Boland KG, Hayles AN, Miller CB, et al. Regional immune response to immunization with Escherichia coli O157:H7-derived intimin in cattle. Clin Vaccine Immunol 2013; 20: 562571.

    • Search Google Scholar
    • Export Citation
  • 43. Stanley AC, Buxton D, Innes EA, et al. Intranasal immunisation with Toxoplasma gondii tachyzoite antigen encapsulated into PLG microspheres induces humoral and cell-mediated immunity in sheep. Vaccine 2004; 22: 39293941.

    • Search Google Scholar
    • Export Citation
  • 44. Shen X, Lagergård T, Yang Y, et al. Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine. Infect Immun 2000; 68: 57495755.

    • Search Google Scholar
    • Export Citation
  • 45. Mapletoft JW, Latimer L, Babiuk LA, et al. Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies. Clin Vaccine Immunol 2010; 17: 2335.

    • Search Google Scholar
    • Export Citation
  • 46. Liu Z, Yuan F, Yang Y, et al. Partial protective immunity against toxoplasmosis in mice elicited by recombinant Toxoplasma gondii malate dehydrogenase. Vaccine 2016; 34: 989994.

    • Search Google Scholar
    • Export Citation
  • 47. Pugh GW Jr, Hughes DE. Bovine infectious keratoconjunctivitis: carrier state of Moraxella bovis and the development of preventive measures against disease. J Am Vet Med Assoc 1975; 167: 310313.

    • Search Google Scholar
    • Export Citation
  • 48. Angelos JA, Hess JF, George LW. An RTX operon in hemolytic Moraxella bovis is absent from nonhemolytic strains. Vet Microbiol 2003; 92: 363377.

    • Search Google Scholar
    • Export Citation
  • 49. Misiura M. Estimation of fimbrial vaccine effectiveness in protection against keratoconjunctivitis infectiosa in calves considering different routes of introducing vaccine antigene. Arch Vet Pol 1994; 34: 177186.

    • Search Google Scholar
    • Export Citation
  • 50. Zbrun MV, Zielinski GC, Piscitelli HC, et al. Evaluation of anti-Moraxella bovis pili immunoglobulin-A in tears following intranasal vaccination of cattle. Res Vet Sci 2012; 93: 183189.

    • Search Google Scholar
    • Export Citation
  • 51. di Girolamo FA, Sabatini DJ, Fasan RA, et al. Evaluation of cytokines as adjuvants of infectious bovine keratoconjunctivitis vaccines. Vet Immunol Immunopathol 2012; 145: 563566.

    • Search Google Scholar
    • Export Citation

Advertisement

Systemic and ocular immune responses in cattle following intranasal vaccination with precipitated or partially solubilized recombinant Moraxella bovis cytotoxin adjuvanted with polyacrylic acid

John A. Angelos DVM, PhD1, Munashe Chigerwe BVSc, PhD2, Judy M. Edman BS3, and John F. Hess PhD4
View More View Less
  • 1 Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616.
  • | 2 Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616.
  • | 3 Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616.
  • | 4 Department of Cell Biology and Human Anatomy, School of Medicine, University of California-Davis, Davis, CA 95616.

Abstract

OBJECTIVE To evaluate changes in systemic and ocular antibody responses of steers following intranasal vaccination with precipitated or partially solubilized recombinant Moraxella bovis cytotoxin (MbxA).

ANIMALS 13 Angus steers with ages ranging from 318 to 389 days and weights ranging from 352 to 437 kg.

PROCEDURES Steers were assigned to receive 500 μg of a precipitated (MbxA-P; n = 5) or partially solubilized (MbxA-S; 5) recombinant MbxA subunit adjuvanted with polyacrylic acid. A control group (n = 3) received the adjuvant alone. Each steer received the assigned treatment (1 mL/nostril) on days 0 and 28. Serum and tear samples were collected on days 0 (before vaccination), 14, 28, 42, and 55. Changes in MbxA-neutralizing antibody titers and MbxA-specific IgG concentrations in serum and tears and changes in MbxA-specific IgA concentrations in tears were measured.

RESULTS Mean fold changes in MbxA-specific IgG concentration in serum and tears and MbxA-neutralizing antibody titer in tears for the MbxA-P group were significantly greater than those for the MbxA-S and control groups. Mean serum MbxA-neutralizing antibody titer did not differ among the 3 groups. Although the mean fold change in tear MbxA-specific IgA concentration differed significantly among the groups in the overall analysis, post hoc comparisons failed to identify any significant pairwise differences.

CONCLUSIONS AND CLINICAL RELEVANCE Systemic and ocular immune responses induced by intranasal administration of the MbxA-P vaccine were superior to those induced by the MbxA-S vaccine. Additional research is necessary to determine whether the MbxA-P vaccine can prevent naturally occurring infectious bovine keratoconjunctivitis.

Contributor Notes

Address correspondence to Dr. Angelos (jaangelos@ucdavis.edu).